Page 38 - Coronavirus Vaccine

Free Covid-19 vaccination campaign lifted booster dose coverage: Govt

From a daily average of 4.7 lakh doses per day till July 15, the number of precaution shots went up to 20.4 lakh per day (from July 15 till date)

Goa to administer 10.5L Covid-19 precautionary doses in next two months

Goa Health Department has set a target to administer precautionary doses of Covid-19 vaccine to 10.5 lakh people in next two months, for which it has decided to rope in various departments.

Data story: India logs 14,830 new Covid cases, active tally at 147,512

India has so far administered 2,025,057,717 vaccine doses

White House to discuss new generation Covid-19 vaccine as Biden recovers

As President Biden continues to recover from his coronavirus infection, the White House plans to hold a summit on Tuesday to discuss developing a new generation of vaccines.

Delhi logs 463 new Covid-19 cases, 2 deaths; positivity rate at 8.18%

Delhi logged 463 fresh coronavirus cases and two fatalities due to the disease as the positivity rate climbed to 8.18 per cent, highest in over a month, according to city health department data.

Telangana plans door-to-door campaign to administer booster dose

In the light of increasing Covid-19 cases, health authorities in Telangana are planning door-to-door drive to administer booster doses to everyone.

Data story: India logs 16,866 new cases, active infections see net decline

India has added 138,087 cases in the past 7 days

1.8 mn Covid vaccine jabs administered during mega drive in Tamil Nadu

Tamil Nadu on Sunday inoculated 18.08 people against COVID-19 in the 32nd mega vaccination exercise in the state, the health department said

3.54 cr people yet to receive booster dose in Tamil Nadu: Health Minister

Currently 3.54 crore in Tamil Nadu are yet to receive the COVID-19 precautionary dose even after completing the six-month period after the second dose

40 mn didn't take even a single dose of Covid vaccine as on July 18: Govt

An estimated 4 crore eligible beneficiaries have not taken even a single dose of COVID-19 vaccine as on July 18, Minister of State for Health Bharati Pravin Pawar informed the Lok Sabha on Friday

Nasal sprays will be essential to tackle emerging Covid-19 variants: Study

Researchers noted that the widely available Covid-19 vaccinations keeping the majority of the population free from serious illness will not be enough to stop the spread of the virus and its variants.

10-20% Covid-affected people experience long-term effects: Health ministry

global evidence suggests 10-20% of people who develop COVID-19 experience a variety of mid- and long-term effects after they recover from their initial illness, the Lok Sabha was informed.

Govt asks all depts to organise free Covid vaccination camps at workplaces

The Centre has asked all its departments to organise Covid vaccination camps at the workplaces for providing free precaution doses of the vaccine to the eligible employees and their family members

Data story: India logs 21,880 new Covid cases, death toll reaches 525,930

India has added 137,038 cases in the past 7 days

Biological E to invest Rs 1,800 cr to augment vaccine capacity, R&D

: Vaccine maker Biological E on Thursday announced its expansion plans for investment of over Rs 1,800 crore, which will generate employment of more than 2500 people in their three facilities in Genome Valley here. According to a press release issued by the state government, the expansion is primarily targeted to ramp up the manufacturing of vaccines along with generic Injectables and R&D. The announcement was made after IT and Industries Minister KT Rama Rao's meeting with leadership of Biological E Mahima Datla, Managing Director. Rama Rao said, I'm delighted to announce the expansion plans of Biological E in Genome Valley. Hyderabad is already known as the vaccine Capital of the World and this expansion further accelerates our strength to serve the world with live saving vaccines. The investment from Biological E will enhance the capacity by five billion doses increasing the cumulative capacity to about 14 billion doses each year. Mahima Datla, Managing Director of ...

US CDC recommends Novavax's Covid-19 vaccine for adults, says report

The US Centers for Disease Control and Prevention (CDC) has endorsed recommendation that Novavax's Covid-19 vaccine be used as another primary series option for adults aged 18 years and older

France plans 2nd Covid-19 booster dose for adults aged 18-59: Report

France will offer a second Covid-19 booster jab to at-risk adults aged from 18 to 59, as well as pregnant women and those who live with vulnerable or immunocompromised people, Le Parisien reported

Centre asks states to increase testing, vaccination amid recent Covid surge

Reviews Covid-19 situation in nine states where test positivity rates have been rising

Covaxin third shot gives long-term immunity: Nature Scientific study

Study shows booster jab is effective against several Sars-CoV-2 strains such as Alpha, Beta, Delta, Delta Plus and Omicron, and also increases memory B-cell response

Covaxin's booster dose demonstrates immunity, says Bharat Biotech

Pharmaceutical major Bharat Biotech on Wednesday said its COVID-19 vaccine Covaxin has proven to be safe, well-tolerated, and immunogenic in subjects in controlled clinical trials. The study has been accepted and published in Nature Scientific Reports, a high impact factor journal. A press release from the vaccine maker said the study was conducted in 184 subjects, who were randomised 1:1 and received either a booster dose of Covaxin or a placebo, six months after the primary series of two doses. Subjects were evaluated for safety, neutralising antibody responses against variants of concern, binding antibodies against spike protein, RBD, N proteins, and for memory T and B cell responses to demonstrate cell-mediated immunity, it said. Krishna Ella, chairman and managing director, Bharat Biotech, said the team has now demonstrated that Covaxin is a multi-epitope vaccine with antibodies against spike, RBD and N proteins. "Post booster dose, it has proven neutralising antibody respons